Trial Profile
A Phase 2 Study of Nivolumab Plus Ipilimumab in Previously Treated Classical Kaposi Sarcoma (CKS)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Kaposi's sarcoma
- Focus Therapeutic Use
- 23 Mar 2022 Results (n=18) published in the Annals of Oncology
- 31 May 2020 Interim results (n=15) assessing efficacy of nivolumab and ipilimumab in patients with Kaposi sarcoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Interim results (Data between April 2018- Feb 2019, n=10) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.